30.6 C
Vientiane
Sunday, June 22, 2025
spot_img
Home Blog Page 967

Michter’s Adds to Its Legacy Series With First Release of Bomberger’s PFG™: Kentucky Straight Bourbon Finished in Precision Fine Grain Oak Barrels

LOUISVILLE, Ky., Jan. 28, 2025 /PRNewswire/ — The year 2025 marks the first release of Bomberger’s PFG (Precision Fine Grain) Kentucky Straight Bourbon. “Over the years, our flagship Bomberger’s Declaration Bourbon has always had a rich, bold nature that I love. This new Bomberger’s PFG release continues our efforts to further experiment with Bomberger’s and push the boundaries of American whiskey. It’s a wonderful expression with great texture and a remarkable spectrum of rich, full flavors resulting from our team’s thoughtful exploration of wood science under very specific conditions,” commented Michter’s Master Distiller Dan McKee.

Bomberger's PFG™: Kentucky Straight Bourbon Finished in Precision Fine Grain Oak Barrels
Bomberger’s PFG™: Kentucky Straight Bourbon Finished in Precision Fine Grain Oak Barrels

Bomberger’s PFG is made by first aging Kentucky Straight Bourbon in a new toasted and charred American oak barrel. After full maturation, the Kentucky Straight Bourbon is removed from the first barrel and placed in a second new, custom, proprietary toasted and charred French fine grain oak barrel of the most exacting specifications. These barrels are toasted at a tightly defined temperature range for a precise period of time before they receive a select charring. The whiskey is matured in these second barrels before being dumped into small batches that undergo our signature filtration prior to bottling at 100.2 proof (50.1% ABV). 

The Bomberger’s PFG finishing barrel is a blend of wood from various origins, including the revered Tronçais, Allier, Nevers, and Vosges forests. It is constructed from wood that has been naturally air dried outdoors for a minimum of 40 months in France near the Charente River, which has a unique seasoning environment influenced by humidity, microflora creation, climate, wind direction, and elevation. After this seasoning, the staves are hand selected to construct the Bomberger’s PFG finishing barrels.

The focus is to be precise at every step of the Bomberger’s PFG production process. Michter’s Master of Maturation Andrea Wilson remarked, “The result is a medley of engaging aromas from confectionary to floral, a palate of beautifully integrated fruits and herbaceous notes with a full body and a luxurious, creamy texture that lingers with soft spice and chocolate.”

The suggested retail price in the U.S. for a 750ml bottle of Bomberger’s PFG is $140.

With its Shenk’s and Bomberger’s Legacy release whiskeys, Kentucky Michter’s honors the heritage of the Pennsylvania distillery founded as Shenk’s in 1753 and renamed Bomberger’s in the 1800’s before becoming known as Michter’s in the 20th century.

For more information about Michter’s, please visit michters.com, and follow us on InstagramFacebook, and X.

Contact:
Joseph J. Magliocco
+1 (502) 774-2300 x580
jmagliocco@michters.com

 

Spectra Medical, XL Precision Technologies Announce Rebrand as Elevaris Medical Devices

Legacy of Trust and Expertise Ushers in New Era of Precision Medical Device Development and Manufacturing Capabilities

BOSTON, Jan. 28, 2025 /PRNewswire/ — Spectra Medical Devices (Spectra) and XL Precision Technologies (XLPT) announced today their newly combined brand presence as Elevaris Medical Devices, a world-class Contract Development and Manufacturing Organization (CDMO) leveraging a proven legacy of excellence to usher in a new era of precision medical device development and manufacturing capabilities.

 

Elevaris_animated_logo_video

The Spectra acquisition of XLPT, announced in September 2024 by healthcare technology and services investor QHP Capital, brought together the companies’ complementary strengths in servicing medical device manufacturers from large-scale Original Equipment Manufacturers (OEMs) to start-ups. Spectra has long been highly regarded for the expansive engineering and manufacturing capabilities and expert technical customer support it provides OEMs. XLPT is widely admired for its specialty manufacturing expertise in precision micro-components, complex tubular components, and sub-assemblies.

Today’s announcement marks the formal evolution to a unified brand that equally honors the rich history of each company and embodies their combined commitment to providing their deep knowledge, unparalleled collaborative approach, and extensive precision manufacturing capabilities to customers worldwide. The decision to establish a new company name and brand identity reflects the promise to apply the best practices and strengths of the individual brands while also emphasizing a singular commitment to elevating customer outcomes to the next level.

“The acquisition late last year brought together two long-trusted companies with highly complementary capabilities,” Richard Zrebiec, CEO of Elevaris Medical Devices, said. “Today, as we complete integration, we believe operating under one brand demonstrates our combined commitment to our customers’ success.”

As the newly branded company, Elevaris Medical Devices will serve medical device companies in an unrivaled capacity. The unified team of engineering, design, and development experts is highly invested in applying its deep knowledge and product perspective to provide value-driven design, development and production solutions that support the success of customer projects. 

“From concept, to design and development, through manufacturing, we are uniquely qualified to support our customers in their quest to develop next-generation medical devices that enable the future of healthcare and improve global health,” Zrebiec said. “Elevaris Medical Devices has the capability to be the preferred partner to drive a new era of precision medical device development and manufacturing.”

About Elevaris Medical Devices: 

Elevaris Medical Devices is a Contract Development and Manufacturing Organization (CDMO) for industry-leading, multi-national healthcare companies, global Original Equipment Manufacturers (OEMs), and emerging technology companies. It is one of the world’s leading manufacturers of made-to-spec procedural needles and specializes in the manufacture of precision micro-components, complex tubular components, and sub-assemblies for the medical device industry. The company also distributes a wide range of complementary pharmaceutical products, surgical instruments, and medical supplies.

Elevaris Medical Devices has more than 300 employees across its locations in North America, the UK, and South Korea. For more information, visit elevarismedical.com.

Getinge Year End Report 2024: Strong order intake and increased sales contributed to sharp improvement in margins

GOTHENBURG, Sweden, Jan. 28, 2025 /PRNewswire/ — “In 2024, Getinge had record sales and we finished off the year with a strong quarter. Both order intake and net sales increased significantly, also organically, with positive performance in all regions”, says Mattias Perjos, CEO of Getinge.

Growth was particularly strong in ventilators, where Getinge is benefiting from the consolidation in the market. Furthermore, consumables in ECLS in Acute Care Therapies and Sterile Transfer in Life Science, showed solid performance.

Paragonix Technologies, Inc., which was acquired in Q3 2024, reported impressive growth in the quarter. The KidneyVault portable renal perfusion system, which addresses the largest organ transplant market in terms of volume, received FDA 510(k) clearance. This means that Paragonix now has unique breadth in its product portfolio, which encompasses all major organ categories.

Getinge’s focus on structural measures to increase productivity and cost efficiency contributed to the operating margin strengthening significantly compared with Q4 2023.

“The strong cash flow and earnings in the quarter highlight the leverage we have in terms of profitability when we achieve higher sales,” says Mattias Perjos.

After the board’s review, Getinge has initiated a process with the strategic intention to phase-out the Surgical Perfusion product category, to further strengthen the company’s long-term growth and profitability. This would contribute marginally positive to adjusted EBITA from 2025 and gradually increase onwards, thanks to reallocation of resources to attractive areas such as ECLS and Transplant Care. Getinge’s market share in Surgical Perfusion is not satisfactory and the market growth is limited.

Despite geopolitical uncertainty and potential trade barriers, demand is expected to be relatively stable, with long-term care needs and hospitals’ willingness to invest as continued strong drivers.

“In 2024, we have demonstrated that we are well positioned in prioritized product categories for our customers. This means that we have a positive outlook on 2025 and expect organic sales growth of 2-5% for the full year,” says Mattias Perjos.

October – December 2024 in brief

  • Net sales increased organically by 9.2% (10.1) and the order intake rose by 7.4% organically (-2.4).
    • Adjusted gross profit amounted to SEK 5,604 M (4,596) and the margin was 50.6% (46.4).
    • Adjusted EBITA amounted to SEK 2,143 M (1,318) and the margin was 19.4% (13.3).
    • Adjusted earnings per share amounted to SEK 5.28 (3.11).
    • Free cash flow amounted to SEK 1,693 M (976).
    • Initiated process with the intention of discontinuing Surgical Perfusion.

January – December 2024 in brief

•    Net sales increased organically by 4.9% (6.4) and the order intake rose by 6.3% organically (-1.6).
•    Adjusted gross profit amounted to SEK 17,409 M (15,533) and the margin was 50.1% (48.8).
•    Adjusted EBITA amounted to SEK 4,869 M (3,887) and the margin was 14.0% (12.2).
•    Adjusted earnings per share amounted to SEK 11.73 (9.19).
•    Free cash flow amounted to SEK 3,284 M (1,623).
•    A dividend per share of SEK 4.60 (4.40) is proposed.

Phone Conference

A conference call will be held on January 28, 2025, at 10:00-11:00 a.m. CET hosted by Mattias Perjos, President & CEO, and Agneta Palmér, CFO.
To participate via teleconference, please register via https://conference.financialhearings.com/teleconference/?id=5002483. After registration, you will be provided with telephone numbers and a conference ID to access the conference. You can ask questions verbally via the telephone conference. During the conference call a presentation will be held. To access the presentation through webcast, please use https://getinge.events.inderes.com/q4-report-2024, where a recorded version can be accessed for 3 years.

Contact:

David Kördel, Head of Investor Relations
Phone: +46 (0)10 335 0077
Email: david.kordel@getinge.com
This information is such that Getinge AB is obliged to make public pursuant to the EU Market Abuse Regulation. The
information was submitted for publication, through the agency of the contact person set out above, on January 28, 2025, at 08:00 am CET.

About Getinge

With a firm belief that every person and community should have access to the best possible care, Getinge provides hospitals and life science institutions with products and solutions that aim to improve clinical results and optimize workflows. The offering includes products and solutions for intensive care, cardiovascular procedures, operating rooms, sterile reprocessing and life science. Getinge employs approximately 12,000 people worldwide and the products are sold in more than 135 countries.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/getinge/r/getinge-year-end-report-2024–strong-order-intake-and-increased-sales-contributed-to-sharp-improveme,c4090524

The following files are available for download:

https://mb.cision.com/Main/942/4090524/3228122.pdf

Getinge – Report for Q4 and Full year 2024

https://mb.cision.com/Public/942/4090524/8f84d5d0c0bbda10.pdf

Press Release – Getinge Year End Report 2024

Fascinating Chinese New Year Gala arrangements of GRT Pearl River Channel in Yunfu Branch Venue

GUANGZHOU, China, Jan. 28, 2025 /PRNewswire/ — A news report from GDToday:

The Pearl River Channel of Guangdong Radio and Television Station’s program “2025 Chinese New Year Gala—Better Lives in Guangdong“, with its renowned performance team and creative content, has attracted a lot of local people to the Yunfu Branch Venue during its rehearsal.

The Modao Mountain Site is an important symbol of Yunfu’s historical and cultural heritage and is the earliest ancient human cultural site in Guangdong. It serves as the background of the virtual program “Adventure to Modao Mountain Site”. It provides a creative introduction to the national intangible cultural heritage Helou Dance, expressing people’s eternal hope for a better life.

A photo of the virtual program "Adventure to Modao Mountain Site"
A photo of the virtual program “Adventure to Modao Mountain Site”

The music video “Yunfu” covers the landmarks across the city, aiming to drive the development of Yunfu’s tourism. The lyrics deliver a Spring Festival blessing to the audience, imbued with Yunfu’s characteristics.

A photo of the music video "Yunfu"
A photo of the music video “Yunfu”

The reality show “Huang Junying’s New Year Wish” features harmonious scenes of Song Jiaqi, Ruan Zhaoxiang, Xu Zhaohao and Huang Junying celebrating the festival in Yunfu, such as planning the village Spring Festival Gala and preparing a table of Yunfu cuisine.


The interactive magic show “Welcome to Yunfu” presents a table of family reunion feast with Yunfu’s specialty agricultural products. The trio, consisting of Song Jiaqi from Guangdong, Hong Kong comedy star Ruan Zhaoxiang, and popular singer Xu Zhaohao, has sparked waves of laughter among the audience.

A photo of the interactive magic show "Welcome to Yunfu"
A photo of the interactive magic show “Welcome to Yunfu”

Yunfu, located in northern Guangdong, is known as the “Stone Capital of China“. The skit “Stone Capital Encounter” is set in a stone market, allowing the audience to appreciate the beauty of Yunfu’s stone while indulging in the humorous verbal battle.

A photo of the skit "Stone Capital Encounter"
A photo of the skit “Stone Capital Encounter”

Yunfu is home to seedless Wampee. The crosstalk show “Dreaming of Yunfu”, featuring well-known Cantonese comedians Wu Haijie and He Zhifeng, brings the audience to Yu’nan County to witness rural revitalization.

The program “2025 Chinese New Year Gala—Better Lives in Guangdong” presented by the Pearl River Channel of Guangdong Radio and Television Station showcases the unique charm of Yunfu—an eco-friendly and internationalized city.

On January 28, let us explore Yunfu’s highlights on the program “2025 Chinese New Year Gala—Better Lives in Guangdong” presented by the Pearl River Channel of Guangdong Radio and Television Station.

Xiao-I Corporation Delivers Transformative AI-Powered HR Solution to Hong Kong Public Sector, Showcasing Scalable MaaS Excellence

ROCKVILLE, Md., Jan. 28, 2025 /PRNewswire/ — Xiao-I Corporation (NASDAQ: AIXI), a leading artificial intelligence company (“Xiao-I”), today announced the successful deployment of its 8-million-HKD AI-powered HR system for a Hong Kong public sector client. This milestone underscores Xiao-I’s growing influence in public sector digitization and highlights the scalability of its Model-as-a-Service (MaaS) platform, which has already driven successful AI adoption across Asia and is poised to support the company’s upcoming U.S. expansion.

The Hua Zang Large Language Model (LLM), the core engine behind the solution, enabled the client to streamline HR operations—including talent management, policy compliance, and employee engagement—with unprecedented efficiency. By leveraging Xiao-I’s proprietary AI architecture, the system achieved high accuracy and transparency while operating on minimal computing resources, reducing both deployment complexity and long-term operational costs.

Key Advantages of the Hua Zang LLM in Public Sector Deployment

  • Rapid Implementation: Pre-trained module libraries cut deployment time by 40%, enabling the client to operationalize the system within weeks.
  • Cost-Effective Scalability: Optimized for low-resource environments, the solution eliminates the need for expensive GPU clusters, aligning with public sector budget constraints.
  • Interpretable AI: Transparent decision-making processes ensure compliance with regulatory standards, fostering trust in automated HR outcomes.
  • Cross-Industry Adaptability: Modular design allows seamless customization for education, healthcare, and other government verticals.

“This project exemplifies how Xiao-I’s AI solutions empower public institutions to modernize efficiently,” said Xiao-I’s CEO Mr. Hui Yuan. “The Hong Kong deployment not only validates our MaaS platform’s versatility but also reinforces our commitment to delivering scalable, ethical AI—principles that will guide our entry into the U.S. market later this year.”

The Hong Kong initiative builds on Xiao-I’s proven track record in Asia, where its AI solutions have been adopted by governments and enterprises for tasks ranging from citizen services to supply chain optimization. The company’s focus on cost-effective, high-impact AI aligns with global demand for technologies that balance performance with fiscal responsibility—a cornerstone of its upcoming U.S. market strategy.

Looking Ahead

Xiao-I plans to replicate this success in North America, tailoring its Hua Zang LLM to address pressing needs in public administration and corporate sectors. The Hong Kong case study will serve as a blueprint for demonstrating how AI can drive operational excellence without prohibitive upfront investments.

About Xiao-I Corporation

Xiao-I Corporation is a leading cognitive intelligence enterprise in China that offers a diverse range of business solutions and services in artificial intelligence, covering natural language processing, voice and image recognition, machine learning, and affective computing. Since its inception in 2001, the Company has developed an extensive portfolio of cognitive intelligence technologies that are highly suitable and have been applied to a wide variety of business cases. Xiao-I powers its cognitive intelligence products and services with its cutting-edge, proprietary AI technologies to enable and promote industrial digitization, intelligent upgrading, and transformation. For more information, please visit: www.xiaoi.com.

Forward-Looking Statements

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company’s ability to achieve its goals and strategies, the Company’s future business development and plans for future business development, including its financial conditions and results of operations, product and service demand and acceptance, reputation and brand, the impact of competition and pricing, changes in technology, government regulations, fluctuations in general economic and business conditions in China, and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the U.S. Securities and Exchange Commission (“SEC”). For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, including under the section entitled “Risk Factors” in its annual report on Form 20-F filed with the SEC on April 30, 2024, as well as its current reports on Form 6-K and other filings, all of which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For investor and media inquiries, please contact:
Ms. Berry Xia
Email: ir@xiaoi.com

SOPHiA GENETICS Launches Comprehensive MRD Tracking Capabilities

The cutting-edge OncoPortal™ Mutation Tracker add-on module enables precision monitoring of evolving genomic cancer drivers

BOSTON, MA and ROLLE, Switzerland, Jan. 28, 2025 /PRNewswire/ — SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, has unveiled the OncoPortal™ Mutation Tracker — a longitudinal MRD tracking tool designed for disease monitoring in the context of oncology. This innovation underscores SOPHiA GENETICS’ commitment to advancing data-driven approaches for improved oncology insights.

Tracking genomic variants across multiple time points in the same patient is becoming increasingly critical in cancer care, particularly for identifying treatment resistance or detecting residual cancer cells, such as in Measurable Residual Disease (MRD) management. The integration of longitudinal tracking capabilities with next-generation sequencing (NGS) allow the parallel detection of cancer-specific genetic mutations at very low frequencies. This combined approach enables early identification of residual disease or emerging variants, providing a more precise assessment of disease burden, better stratification of high-risk patients, and the ability to tailor treatments to the cancer’s unique genomic profile.

The OncoPortal™ Mutation Tracker augments the SOPHiA DDM™ Platform’s core analytical capabilities to allow clinical researchers to longitudinally monitor evolving genomic variants across multiple time points, providing a comprehensive view of disease evolution. The OncoPortal™ Mutation Tracker enhances workflow efficiency for longitudinal variant tracking by offering flexible low frequency variant selection, customizable threshold settings, and reporting features to generate longitudinal graphical representations, simplifying the process of tracking and analyzing genetic changes over time.

“The ability to reliably track low frequency variants longitudinally is a game-changer because it allows the detection of even the smallest traces of cancer that can evade traditional methods of testing and ultimately drive relapse,” said Philippe Menu, M.D., Ph.D., Chief Medical Officer and Chief Product Officer, SOPHiA GENETICS. “With this new longitudinal tracking capability, we offer a highly customizable, user-friendly solution to enable the generation of novel insights for clinical research. Precise tracking of key genomic variants over time has the potential to eventually enable earlier intervention and more tailored disease management, which may lead to better long-term outcomes for patients.”

“This longitudinal interface represents the solution we’ve been seeking to unite our oncologists in embracing broader adoption of NGS. It’s the missing piece that unlocks a new frontier in personalized, data-driven medicine,” said Dr. Christophe Marzac, Head of the Hematology-Immunology Unit, Gustave Roussy Institute.

For more information on the OncoPortal™ Mutation Tracker, visit SOPHiAGENETICS.com.

About SOPHiA GENETICS 

SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to transform patient care by expanding access to data-driven medicine globally. It is the creator of the SOPHiA DDM™ Platform, which analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.com and connect with us on LinkedIn.

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact support@sophiagenetics.com to obtain the appropriate product information for your country of residence. 

SOPHiA GENETICS Forward-Looking Statements:

This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. 

 

 

NYSE CONTENT ADVISORY: PRE-MARKET UPDATE FOR JANUARY 28th

NEW YORK, Jan. 28, 2025 /PRNewswire/ — The New York Stock Exchange (NYSE) is proud to offer a daily pre-market update directly from the NYSE Trading Floor. Access today’s NYSE Pre-market update for market insights before trading begins. 

 

NYSE Content Advisory: Pre-Market Update for January 28th

Kristen Scholer delivers the pre-market update on January 28th

  • Federal Reserve begins two-day policy meeting today
  • Traders and investors anticipate rates to go unchanged
  • General Motors sees shares rise amid strong profit and sales estimates

Watch NYSE TV Live every weekday 9:00-10:00am ET 

 

TuanChe Announces Plan to Adopt DeepSeek R1 Model to Accelerate Intelligent Technology Upgrades

BEIJING, Jan. 28, 2025 /PRNewswire/ — TuanChe Limited (NASDAQ: TC) (“TuanChe” or the “Company”), a leading automotive marketplace platform, today announced its plan to adopt DeepSeek’s newly released R1 model as the technological foundation for its intelligent service system. This initiative aims to further enhance TuanChe’s technological capabilities in smart marketing and user interaction, delivering more precise, efficient, and intelligent automotive consumption experiences for its users.

The DeepSeek R1 model has enhanced its advanced reasoning capabilities through a multi-stage loop training approach, demonstrating exceptional performance in mathematical operations, code analysis, and natural language reasoning tasks. Notably, its breakthroughs in reinforcement learning allow DeepSeek R1 to autonomously learn complex reasoning strategies through self-play and evolution without reliance on extensive labeled data.

TuanChe has consistently focused on improving platform service efficiency and user experience through independent research and technology optimization. The selection of the DeepSeek R1 model underscores its robust reasoning abilities and self-learning characteristics. By deeply integrating the R1 model, TuanChe will optimize its user data analysis processes and intelligent recommendation systems, enhancing the accuracy and efficiency of its services.

TuanChe plans to incorporate the DeepSeek R1 model into its intelligent marketing and interaction platform, leveraging R1’s deep learning algorithms to comprehensively analyze user behavior and market data. This will enable more personalized service recommendations. Additionally, the open-source nature of the R1 model provides TuanChe with the flexibility for secondary development and scenario-specific applications, allowing the company to meet diverse customer needs and business requirements.

TuanChe stated that adopting DeepSeek R1 is a significant milestone in its digital and intelligent strategic upgrade. Looking ahead, TuanChe will continue to introduce innovative technologies and services to further enhance its users’ automotive consumption experience.”
With the gradual integration of DeepSeek R1 into its operations, TuanChe is expected to deliver smarter, more personalized services to its users in the near future, driving the digital transformation of the automotive marketplace. This strategic decision not only injects new momentum into TuanChe’s growth but also paves the way for the application of intelligent technologies in the automotive industry.

About TuanChe Limited

Founded in 2010, TuanChe Limited (NASDAQ: TC) is China’s leading automotive marketplace platform. TuanChe is dedicated to connecting automotive consumers with manufacturers, dealers, and service providers. By integrating its digital platforms with offline sales events, TuanChe offers comprehensive automotive marketing and transaction services. Through its integrated marketing strategies, TuanChe transforms individual and independent car purchases into large-scale group buying experiences, using an interactive many-to-many model.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, the Company’s business plans and development, business outlook, which can be identified by terminology such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. Such statements are based upon management’s current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company’s control. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the U.S. Securities and Exchange Commission. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.

Media Enquiries:

Lydia Hu
lydia.hu@tuanche.com